Analyst Research Roundup: Arbutus Biopharma Corporation (ABUS), Synthetic Biologics, Inc. (SYN)

Arbutus Biopharma Corporation (NASDAQ:ABUS) tinted loss of -4.07% (-0.15 points) to US$3.54. The volume of 0.13 Million shares climbed down over an trading activity of 230.34 Million shares. EPS ratio determined by looking at last 12 month figures is -1.81. Over the same time span, the stock marked US$12.6 as its best level and the lowest price reached was US$3.2. The corporation has a market cap of US$209.14 Million.

Arbutus Biopharma Corporation (NASDAQ:ABUS)’s earnings per share has been growing at a -23.8 percent rate over the past 5 year when average revenue increase was noted as -5.4 percent. The return on equity ratio or ROE stands at -72.9 percent while most common profitability ratio return on investment (ROI) was -72.5 percent. The company’s institutional ownership is monitored at 43.6 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Synthetic Biologics, Inc. (NYSE:SYN) is worth US$8.48 Million and has recently fallen -5.8% to US$0.65. The latest exchange of 0.26 Million shares is below its average trading activity of 350.74 Million shares. The day began at US$0.69 but the price moved to US$0.65 at one point during the trading and finally capitulating to a session high of US$0.69. The stock tapped a 52-week high of US$20.29 while the mean 12-month price target for the shares is US$4.42.

Currently, the stock carries a price to earnings ratio of 0.17, a price to book ratio of 0, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 60.7%. With an institutional ownership near 11.8%, it carries an earnings per share ratio of 3.89.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.5.